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Abstract:  Millions  of  blood  products  are  transfused  every  year;  many  lives  are  thus 
directly concerned by transfusion. The three main labile blood products used in transfusion 
are erythrocyte concentrates, platelet concentrates and fresh frozen plasma. Each of these 
products has to be stored according to its particular components. However, during storage, 
modifications or degradation of those components may occur, and are known as storage 
lesions. Thus, biomarker discovery of in vivo blood aging as well as in vitro labile blood 
products  storage  lesions  is  of  high  interest  for  the  transfusion  medicine  community.  
Pre-analytical  issues  are  of  major  importance  in  analyzing  the  various  blood  products 
during storage conditions as well as according to various protocols that are currently used 
in blood banks for their preparations. This paper will review key elements that have to be 
taken into account in the context of proteomic-based biomarker discovery applied to blood 
banking. 
Keywords:  labile blood products; aging and storage lesions; biomarkers; pre-analytics; 
proteomics 
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1. Blood Components Preparation and Storage 
Whole blood transfusion is nowadays realized in very limited cases. Indeed, transfusion therapy 
now mainly relies on administration of the blood component really needed by the patients. The three 
main labile blood components used in transfusion therapy are erythrocyte concentrates (ECs), platelet 
concentrates (PCs) and fresh frozen plasma (FFP). These products can be obtained either by processing 
a whole blood donation (450–500 mL), which is the most common and simplest technique, or by 
apheresis where only the needed component is taken from the donor, the remainder been returned to 
the donor [1]. This last technique is more expensive and requires a more consistent facility.  
The standard procedure of blood products preparation from whole blood donation is as follows: 
once collected in plastic bags containing citrate phosphate dextrose (CPD) anticoagulant, whole blood 
is centrifuged in order to separate blood cells according to their size and density. Red blood cells 
(RBCs) settle, while plasma remains on the top. White blood cells and platelets (PLTs) form a “buffy 
coat”  layer  at  the  interface.  Finally,  the  three  components  are  distributed  among  the  sterile  
inter-connected blood bags by applying a semi-automated pressure to the centrifuged bag containing 
the original whole blood donation.  
In order to prevent various post-transfusion reactions and anti-HLA allo-immunisation, whole blood 
donation is impoverished in white cells by filtration (erythrocyte plasticity allows to pass through the 
membranes,  contrary  to  white  cells  that  are  retained).  Indeed,  as  leukocytes  could  be  pathogens 
containing  cells,  blood  products  are  systematically  leukodepleted.  A  retrospective  study  has 
demonstrated that the rates of febrile nonhemolytic transfusion reactions (FNHTRs) are decreased by a 
factor  of  1.7  and  4.1  after  RBCs  and  PCs  transfusion  respectively,  since  the  establishment  of 
systematic prestorage leukodepletion [2]. 
Each  component  obtained  from  whole  blood  has  optimal  storage  conditions,  which  permits  to 
preserve  its  specific  activities  and  functions.  The  temperature  is  a  particularly  important  storage 
parameter regarding the viability and the quality of products intended for transfusion. Supplemented 
with an additive solution, generally a saline-adenine-glucose-mannitol (SAGM) solution, RBCs can be 
stored for up to 42 days from +2 ° C to +6 ° C, in order to preserve the functionalities of erythrocytes. 
On the contrary, PLT are stored from +20 ° C to +24 °C  up to 5 days, with sufficient agitation to permit 
a  good  oxygenation  and  to  prevent  platelet  aggregation.  Storage  at  room  temperature  promotes 
bacterial  proliferation,  and  thus  increases  the  risk  of  transmitted  bacteria.  The  dilemma  is  that  if 
platelets  are  transfused  after  refrigeration  at  4  ° C,  they  are  rapidly  cleared  from  the  recipient 
circulation [3]. Finally, as indicated by its name, FFP has to be frozen, for an optimal storage, at least 
at −25 °C , for up to 36 months. 
These limits depend on local legislation, and depend on the additive solutions used in erythrocyte 
and platelet concentrates. These three labile blood products can be further differentially processed 
depending on demand for particular biomedical needs (-irradiation, washing and so on). 
2. Blood Products Storage Lesions 
Even  under  current  optimal  storage  conditions,  modifications  and/or  degradation  of  blood 
components occur in blood bags. These alterations, known as “storage lesions”, affect lifespan and Int. J. Mol. Sci. 2010, 11                       
 
 
4603 
quality of the stored blood products [4]. Even though it is unknown if storage lesions are consequences 
of the natural aging of blood components, these lesions are well described in the literature.  
2.1. Erythrocyte Concentrates Storage Lesions 
Red blood cells storage lesions can be classified in different categories, depending on their physical 
or chemical properties [5,6]. 
First, some biochemical changes related to the energy metabolism occur. It appears that components 
such  as  ATP,  which  is  necessary  for  multiple  cellular  processes,  and  2,3-DPG,  which  plays  an 
important  role  in  oxygen  release,  rapidly  decrease  during  the  storage.  ATP  level  is  considerably 
diminished after 5 weeks of storage while the 2,3-DPG is almost null after 2 weeks of storage [7]. The 
low concentration of 2,3-DPG increases hemoglobin affinity for oxygen, which cannot be delivered 
anymore. However, these levels are rapidly recovered in blood circulation after transfusion of the 
erythrocyte concentrate. It is also known that intracellular sodium and potassium levels are altered 
through storage. Indeed, Na
+/K
+ pumps are inactive at 4 ° C, thus allowing high sodium influx and 
potassium loss [7]. 
Then, RBCs storage induces biomechanical changes. The erythrocytes rheological properties, such 
as shape, deformability, aggregability, and intracellular viscosity are altered during storage [8]. All 
these  changes  impact  the  red  blood  cells  ability  to  pass  through  microvessels,  thus  altering  their 
oxygenation  capacities.  This  is  very  problematic  in  blood  banking,  and  neither  SAGM  nor  
phosphate-adenine-glucose-guanosin-saline-mannitol  (PAGGSM),  the  two  mostly  used  additive 
solutions, are described to prevent these storage lesions [9]. 
Finally, modifications also take place at the protein level. Indeed, erythrocytes are subjected to 
oxidative lesions, which result in protein oxidative modifications [10,11], hemichrome formation and 
Band 3 clustering. Storage-induced protein degradation appears to be greatly reduced when oxygen is 
removed and blood is stored under helium [12]. Antonelou et al. have shown that erythrocyte proteins 
are less oxidized when RBCs are stored in CPD-SAGM compared to storage in CPD-Adenine [13]. 
Mechanisms of oxidative damage along the development of storage lesions and investigations of the 
effect  of  blood  anaerobic  storage  conditions  have  been  recently  described  by  Yoshida  and 
Shevkoplyas [14]. 
Some aspects of RBC aging occurring in vivo and in vitro during storage are similar. For example, 
the  increase  of  intracellular  calcium  level  induces  microvesiculation  and  externalization  of  
negatively-charged membrane phospholipids (phosphatidylserine) [15]. RBCs clearance from blood 
circulation is thought to be immunologically mediated. Several studies have led to the so-called Band 3 
clustering  model [16,17].  Oxidized  hemoglobin  compounds  aggregate  to  form  hemichromes  that 
accumulate at the inner side of erythrocytes membrane, covalently bound with cytoskeletal proteins 
such as spectrin, thus inducing alterations of RBC deformability. Interaction of hemichromes with 
cytoplasmic domains of Band 3 leads to Band 3 clustering. This conformational change of the major 
erythrocyte  membrane  protein  is  recognized  by  naturally  occurring  anti-Band  3  auto-antibodies 
(nAbs) [18–20]. Paleari et al. have demonstrated that the number of these RBC-bound IgGs increases 
in old population enriched fractions (through Percoll density fractionation), as well as in some selected 
clinical cases of patients with altered RBC survival [21]. These observations lead to the conclusion that Int. J. Mol. Sci. 2010, 11                       
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RBC-bound  IgG  is  a  biomarker  of  aging.  Hemicromes,  Band  3  dimerization  and  erythrocyte 
recognition by nAbs are thus additional RBCs aging markers that can be investigated. 
2.2. Platelet Concentrates Storage Lesions 
Platelet  Storage  Lesions  (PSL)  consist  in  morphological  changes,  platelet  activation,  platelet 
proteolysis  and  platelet  surface  receptor  expression [22,23].  Changes  of  platelet  membrane 
glycoproteins are also reported in numerous papers [24–26]. 
The normal platelet discoid shape (also referred as resting shape) is found to be lost after 5 to 7 days 
of storage at 22 ° C. At this storage time, mainly spherical or fragmented platelets remain. Granule 
release  and  platelet  activation  occur  during  PLT  storage,  as  indicated  by  the  accumulation  of  
β-thromboglobulin and platelet factor 4 in the storage medium, and the increase in surface levels of  
P-selectin (CD62P), respectively.  
In  vitro,  loss  of  aggregation  functionality  is  also  observed.  There  is  a  significantly  storage-
dependant  decrease  of  platelet  aggregation  response  to  a  number  of  agonists  used  alone,  such  as 
adenosine  diphosphate  (ADP),  epinephrine,  collagen  and  arachidonic  acid [27].  However,  these 
aggregation agonists seem to have a synergistic action since pairs of them have been shown to restore 
platelet aggregation, even after five days of storage [27]. Shapira et al. have also shown that platelet 
prothrombinase activity and membrane phosphatidylserine exposure are enhanced during PCs blood 
banking storage [28]. 
As blood components natural aging and storage lesions can directly affect cells, and also have 
implications at the protein level, the analysis of biomarkers of such phenomenon must be ruled out by 
important pre-analytical considerations. 
3. Analysis of Blood Products Aging and Storage Lesions Biomarkers: Pre-Analytical Issues 
3.1. Importance of Pre-Analytics in Biomarker Discovery Field 
In  order  to  be  used  in  medicine,  a  biomarker  has  to  be  both  sensitive  and  specific.  Indeed,  a 
biomarker of a given physiological state must allow the identification of this state (sensitivity) and 
must not be relevant to another physiological state (specificity). However, only few of them meet all 
criteria making an efficient biomarker suitable for clinical uses. 
In the field of biomarker discovery, an important issue is to control sample preparation steps and 
pre-analytical factors. Specificities of a biomarker have to be the same everywhere following the same 
protocol. For that reason, the standardization of procedure controlling pre-analytical steps (sampling, 
conservation and preparation) has to be elaborated. 
As discussed before, the three main labile products are differentially processed and stored in order 
to maintain their viability and quality for transfusion therapy. Standards are published by competent 
authorities in each country. However, even if the procedure is similar, there are still minor changes 
applied worldwide. Indeed, blood labile products have to meet definite standards, whatever the way of 
production and the material used. For example, quality of platelet concentrates varies according to the 
platelet additive solution used [29]. Int. J. Mol. Sci. 2010, 11                       
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3.2. Proteomics in Blood Transfusion 
3.2.1. Proteomic Tools for Biomarker Discovery 
Proteomics  has  been  largely  used  in  the  field  of  biomarker  discovery [30,31]  as  well  as  in 
transfusion medicine [32,33] since proteins are the effective form of genes, and are thus more able to 
inform  about  the  physiological  state.  Indeed,  contrary  to  the  genome,  the  proteome  composition 
fluctuates during time, changes among cell population and is physiological state-dependent.  
Clinical proteomics is a major asset for diagnosis, prognosis or evolutionary biomarkers. Varieties 
of improved proteomic technologies allow separation, identification and quantification of proteins, 
here  potential  biomarkers.  Gel-based  technologies  (two-dimensional  gel  electrophoresis,  2DE,  and 
two-dimensional differential gel electrophoresis, 2D-DIGE), as well as chromatographic techniques 
(e.g., reverse phase liquid chromatography, RPLC, and strong cation exchange liquid chromatography, 
SCX-LC) have been developed in order to fractionate proteins or peptides from complex samples. 
Then, proteins can be analyzed by mass spectrometry (MS) consisting in the ionization of proteins or 
peptides in order to identify them according to their mass-to-charge ratio (m/z). The two commonly 
used sources of ionization are matrix-assisted laser desorption/ionization (MALDI) and electrospray 
ionization  (ESI).  MALDI  source  is  preferentially  combined  with  time-of-flight  (TOF)  analyzer, 
whereas the ESI source is coupled with quadrupole (Q), ion trap (IT), fourier transform ion cyclotron 
resonance (FTICR), Orbitrap or combinations of these analyzers. Peptide mass fingerprinting (PMF) or 
de  novo  sequencing  by  tandem  mass  spectrometry  (MS/MS  or  MS² ),  combined  with  powerful 
bioinformatic tools allow protein identification by database interrogation. Protein quantitation [34,35] 
can be achieved thanks to diverse treatments before or after the sampling step [36] (metabolic stable 
isotope labeling of amino acids in cell culture, SILAC [37], and chemical addition of isotope-coded 
affinity  tags,  ICAT [38],  or  isobaric  tags  for  relative  and  absolute  quantitation,  iTRAQ [39]),  by 
spiking samples before MS analysis with known amount of an isotopically labeled analyte (absolute 
quantitation of proteins, AQUA [40]) and even by recently developed label-free methods, based on MS 
or chromatography data-processing (spectral counting [41] or total ion current, TIC, integration [42]). 
Surface  enhanced  lazer  desorption/ionization  time-of-flight  (SELDI-TOF),  also  known  as 
ProteinChip  Array  technology,  is  widely  used  in  biomarker  discovery [43,44].  A  solid-phase 
chromatographic  surface  allows  sample  decomplexification  according  to  chemical  or  biochemical 
properties. Users can design their own chromatographic surface to target specific protein population. 
Bound proteins are then ionized and analyzed as in classical MALDI-TOF MS analysis. However, 
SELDI-TOF MS analysis does not lead to protein identification, but only gives a mass list of proteins 
showing relative abundance differences between samples. Once targeted, these proteins have to be 
further purified then identified by standard mass spectrometry. Caputo et al. have developed such kind 
of  methods  for  protein  identification  on  ProteinChip  surfaces,  i.e.,  on-chip  digestion  and  MS/MS 
sequencing by hybrid quadrupole-TOF [45]. 
Recent advances in all these proteomic techniques have improved reproducibility, but the problem 
of inter-laboratory reproducibility still subsists. To ensure this reproducibility, a control of the initial 
state  of  samples,  with  standardization  of  sample  collection,  storage  and  preparation  conditions,  is 
required. According to Lehmann et al. [46], the following pre-analytical steps have to be controlled: Int. J. Mol. Sci. 2010, 11                       
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the  sampling  procedure  and  the  type  of  container,  the  temperature  and  the  time  before  transport  
(if transport needed), the time between sample collection and sample processing, the process itself 
(centrifugation, aliquoting, type of secondary container), the storage (temperature and duration) and 
the pre-treatment just before proteomic analysis. 
The  general  complexity  of  a  proteome,  and  particularly  the  huge  dynamic  range  of  protein 
abundance composing the blood proteome, makes necessary the fractionation of blood samples before 
proteomic analysis, by depletion or fractionation processes. Then, other sample preparation can be 
required  depending  on  the  type  of  analysis  to  be  performed,  and  cannot  be  standardized  to  all 
biomarker discovery studies. 
3.2.2. Involvement of Proteomics in Blood Transfusion  
3.2.2.1. Erythrocyte Proteome Investigations 
Red blood cell is an abundant and easily obtained biological material having the particularity to be 
nucleus- and organelle-free. These characteristics have made of it a model of choice for membrane 
studies. Nowadays, thanks to development of proteomic tools and technologies, erythrocyte proteome 
begins to be well documented. Several major studies about RBC proteome have been published last 
decade, showing a great improvement in terms of number of identified proteins, in cytosolic as well as 
membrane extracts. 
In 2002, a first study combining one dimensional (sodium dodecyl sulphate polyacrylamide gel 
electrophoresis, SDS-PAGE) and 2D electrophoresis, allows identification of 84 unique proteins from 
ghost  preparation  by  MALDI-TOF  MS  analysis.  Classic  SDS-PAGE  reveals  25  proteins  of  high 
hydrophobicity and high molecular weight, undetectable with 2DE [47]. Two years later, the use of 
LC-MS has enabled Goodman and coworkers to identify 181 proteins after tryptic digestion of both 
cytoplasmic  and  membrane  preparations [48].  Then,  Pasini  et  al.  have  increased  the  number  of 
identified  proteins  to  566  (314  membrane-associated  proteins  and  252  cytoplasmic  proteins), 
combining high-accuracy and high-sensitivity protein identification technologies to analyze trypsin-
digested differentially extracted proteins from cytoplasmic and membrane fractions. They have tested 
different extraction methods leading to differences in number of identified proteins. This number also 
appeared  to  vary  according  to  interrogated  database [49].  In  2008,  the  peptide  ligand  library 
technology [50] made possible the exploration of red blood  cell hidden proteome by reducing the 
erythrocyte dynamic protein concentration range, which permits Roux-Dalvai et al. to identify 1578 
soluble proteins by nano-LC-LTQ-Orbitrap MS/MS analysis [51]. A more recent study reveals 222 
identified proteins. Even though this number may appear low in comparison with other studies, the 
authors  have  set  up  an  interesting  hemoglobin  depletion  strategy,  derived  from  the  existing 
HemogloBind™  reagent [52]. In 2010, van  Gestel  et al. have explored RBC membrane proteome 
combining blue native protein separation (BN/SDS-PAGE), CyDyes labeling-based quantitation and 
LC-MS/MS  identification [53].  This  allowed  them  to  identify  524  proteins,  of  which  155  are 
membrane proteins. The CyDyes labeling led to quantitation of a 40% decrease in spectrin levels in 
erythrocyte  membrane  fraction  of  a  patient  presenting  RBC  membrane  disorder.  This  interesting 
approach thus seems to be applicable to biomarker discovery. Lately, efforts have been made in the Int. J. Mol. Sci. 2010, 11                       
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establishment of interactome and network maps, as reported by Goodman et al. [54] and updated by 
D’Alessandro et al. [55]. 
3.2.2.2. Platelet Proteomic Analyses 
Platelet  quality  was  usually  determined  from  measurable  characteristics  such  as  pH,  platelet 
morphology  and  hypotonic  shock  responses.  Protein  analysis  of  platelets  during  storage  was  first 
achieved  in  the  end  of  the  1980s  by  identifying  variation  in  actin [56,57].  However,  actin 
polymerization is linked to the method used in the preparation of PCs and it has been shown that this 
process is partially reversible after 1 day of storage [58], which is highlighting the implication of  
pre-analytics  in  biomarker  discovery.  Since  the  introduction  of  proteomics,  new  tools  have  been 
brought in order to characterize platelet storage lesions. As explained previously, lesions occur during 
storage of PCs and can alter several proteins and mechanisms. The proteome analysis of platelets 
during the period of storage may  reveal  different  biomarkers, potentially  important  for improving 
platelet quality [59]. Proteomic analysis of platelets  in vivo or during storage was achieved at the 
beginning of the last decade [59,60]. Using gel-based proteomics, different groups identified several 
hundreds to thousands of PLT proteins [61–63]. Based on peptidic-centric methods, 641 proteins were 
reported by Gevaert and coworkers, including hydrophobic membrane proteins [64]. Later, different 
studies have focused on changes during storage periods, typically between a 1-day and a 7-day storage. 
Thiele et al. have shown by DIGE and MS that 97% of cytosolic proteins do not change over a 9-day 
storage period [65]. However, in the 3 remaining percent, they highlighted that, for instance, spetin 2 
and gelsolin show changes in 2DE. They claimed that these proteins, affected during apoptosis, may be 
suitable  markers  for  platelet  alteration  during  storage.  Using  a  similar  approach  but  focusing  on 
supernatant, it has been also shown that levels of proteins increase during storage, which may have 
some implications for transfusion recipients [66]. More recently, Devine and coworkers have used 
complementary proteomic methods (2DE, DIGE, iTRAQ and ICAT) to investigate protein changes 
between days 1 and 7 of PLT storage [67]. Hence, 503 proteins changed concentration was reported 
thus completing the PLT proteome.  
Beyond  these  analyses,  the  impact  of  such  potentially  biomarkers  has  to  be  integrated  within 
molecular mechanisms leading to platelet storage. As explained by Schubert and Devine, biological 
interpretation of proteomic data has to be taken into account [59]. A comprehensive view of different 
mechanisms related to biomarkers may be required to understand how to improve platelet quality. 
Even though such an approach is far to be completed nowadays, changes in molecular mechanisms 
have been described. Schubert et al. have identified 12 proteins connected in one potential signaling 
pathway  underlying  storage  lesion  development [68].  They  have  shown  that  PI3-kinase-dependent 
Rap1 activation leads to integrin IIb3 activation and PLT degranulation. In addition, a PI3-kinase 
inhibitor incubated with PLT for 7 days plays a role in Rap1 activation and seems to improve PLT 
integrity and quality during storage. A global view, including protein-protein interactions [69], is one 
of the tools able to provide a wide picture of the storage lesions and mechanisms involved during such 
modifications. Int. J. Mol. Sci. 2010, 11                       
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All these studies have potential influence on the future of platelet quality and safety during storage, 
and  of  course,  as  it  is  explained  within  this  review,  pre-analytic  considerations  are  inherent  to  
these studies. 
3.3. Blood Proteomics Pre-Analytical Considerations 
All  these  blood-related  studies  can  be  impacted  by  pre-analytics.  From  sample  collection  to 
proteomic  analysis,  all  manipulation  steps  are  source  of  pre-analytical  variation.  The  main  
pre-analytical considerations to take into account are resumed in Table 1. 
3.3.1. Sample Collection 
Blood donation conditions such as the donor position, the time of tourniquet application, and the 
needle bore size are important. In upright position, blood macromolecular component rates can be 
increased, due to a shift in body water from intravascular to interstitial compartment (macromolecules 
cannot pass through blood vessels and are thus concentrated) [70]. The same effect can be noticed if 
the  tourniquet  application  exceeds  one  minute.  Indeed,  proteins  and  macromolecules  can  thus 
accumulate upstream the tourniquet and be detected at a higher rate than normal by this effect of 
concentration. Moreover, Cengiz et al. have shown in a recent study that erythrocyte deformability is 
still altered up to 180 seconds after tourniquet removal, and erythrocyte aggregation is increased up to 
30 seconds  after tourniquet removal [71]. They  also  confirmed that tourniquet application induces 
leukocytes activation. 
Concerning the needle bore size, too thin needle can induce hemolysis, thus free hemoglobin and 
other protein concentrations increase in serum/plasma. It is not problematic when working with blood 
products obtained from whole blood donation because in case of large blood drawn volume, largest 
needles are used (16 to 19-gauge needles). In routine venipuncture, smaller blood volumes are drawn 
and patient comfort is of high importance, thus thinner needles are chosen (21 to 23-gauge needles). 
However, too thin needles (25-gauge needles) should be avoided since it can induce pre-analytical 
variability (hemolysis), leading to false interpretation of test results [72,73].  
3.3.2. Sample Container Type 
All containers have to be tested for a possible interference with analyses to be performed. Indeed, 
containers can salt out plastic components, which can be detected in analysis by mass spectrometry. 
The presence of polymers in an MS analysis induces effect of signal suppression: the high amount of 
ionized polymer saturates the detector, and the other sample minority  components  ions  cannot  be 
detected anymore. In 2004, Drake et al. have demonstrated the presence of polymers on mass spectra 
from extracts of saline solution incubated in different blood sample containers, from two different 
manufacturers [74]. 
Investigating  serum/plasma  proteomes,  Hsieh  et  al.  have  shown  that  there  was  no  significant 
difference between samples collected in glass red-top tubes and samples collected in serum separator 
tiger-top tubes [75]. However, comparing the nature of the anticoagulant used, they have found high 
significant differences in plasma protein profiles. Most common anticoagulants are EDTA, heparin and Int. J. Mol. Sci. 2010, 11                       
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sodium  citrate.  Their  different  action  ways  lead  to  these  differences  in  proteome  composition. 
Moreover, they are also known to interfere with subsequent analysis. EDTA is known to interfere in 
enzymatic activity assays, whereas heparin is not advised for some ELISA-based assay kit.  
3.3.3. Sample Processing and Handling 
First  of all, the time between blood  donation and preparation of the labile products  is  of high 
importance. Banks et al. have shown in 2005 that this duration induces differences in SELDI-TOF 
profiles of plasma collected with different anticoagulants and serum samples [76].  
A study of West-Nielson et al., based on principal component analysis (PCA) of MALDI-TOF 
spectra, reveals that there was no significant difference between spectra of serum from blood left to 
clot up to 24 h at 4 ° C and from blood left to clot up to 4 h at 24 °C  [77]. However, when blood is left 
to clot for longer times at 24 ° C (8 h to 24 h), clearly changes appear in mass spectra, which was 
confirmed later [75]. In 2007, Timms et al. have shown that both transport time and temperature play a 
role on SELDI-TOF spectra profiles of sera [78]. 
Studying RBC microparticles, Rubin et al. have encountered some pre-analytical caveats. Indeed, 
our group has shown that sample processing temperature and vortexing duration affect microparticles 
counting [79]. Dealing with centrifugation force (1500 or 3000 ×  g) and duration (15 vs. 30 minutes), 
serum proteome profiles do not appear to be affected [75].  
Protein  degradations,  such  as  fragmentation  by  proteolysis,  and  protein  modification,  such  as 
oxidation,  have  been  described  as  storage  lesions  (see  part  2).  However,  these  alterations  can  be 
induced during sample manipulation, and cannot be differentiated from storage lesions. The addition of 
protease  inhibitors  to  prevent  handling-related  proteolysis  is  thus  of  high  importance.  If  protease 
inhibitors are omitted, it has been shown that low molecular weight compounds appear and accumulate 
during sample preparation [80]. It is  necessary  to  prevent proteolytic  cleavages  because  generated 
peptides could thus be mistaken for potential biomarker. Indeed, analyzing peptidome variations of 
pathological sera, Davis et al. have shown that modifications in low molecular weight compounds 
reveal  disease-induced  hemostatic  dysregulation  rather  than  direct  protease  activity  of  a  given 
pathology [81]. Indirectly pathologically-induced peptidome variations are not specific enough to be 
considered as good biomarkers and have thus to be avoided by use of protease inhibitors, even if it is 
not known whether all protease activities are repressed.  
RBCs possess a set of enzymes responsible for antioxidant defense (catalase, superoxide dismutase, 
peroxiredoxins and glutathione peroxidase). However, these enzymes can be inactivated by excess of 
reactive  oxygen  species  (ROS),  and  additional  protein  oxidation  can  thus  occur  during  sample 
processing. In order to prevent this phenomenon, particularly prior to cystein oxidation assessment in 
stored RBC redox proteomic studies, cell-permeable cystein-specific reagents, such as iodoacetamide 
(IAA) or N-ethylmaleimide (NEM) alkylating agents, are commonly used [82,83]. 
3.3.4. Sample Storage 
Storage conditions are important to preserve quality of labile blood products and to ensure the 
efficiency of transfusion therapy. Thus, it is known that erythrocyte concentrates are preferentially Int. J. Mol. Sci. 2010, 11                       
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stored at 4 ° C whereas platelet concentrates are stored at 22 ° C to prevent cold activation of platelets. 
Finally, fresh frozen plasma is stored at −25 ° C at least. 
Thus, whole blood storage cannot ensure optimal preservation of each blood components. In labile 
blood products aging field, samples are ECs, PCs or FFPs, and are stored according to blood banking 
legislation. In pathological-case biomarker research, samples are either serum or plasma, and are not 
subject to any storage legislation. Several studies aimed at investigating the reproducibility of analysis 
after storage at −20/−30 ° C or −80 ° C, and after freeze-thaw cycles [75,84,85]. It appears that storage 
at −20 ° C instead of the recommended −80 ° C storage does not induce loss of information. Samples 
stored at −20/−30 ° C can thus be used for biomarker discovery [86].  
Some proteins have been shown to be highly temperature-sensitive: cryoproteins. Described for the 
first time in the 1930’s by Wintrobe  [87] as myeloma’s patient sera precipitating at cold temperature, 
cryoproteins are serum or plasma proteins having the property to precipitate below the  physiological 
temperature.  Most  of  the  time  composed  of  immunoglobulins  (mainly  IgM)  these  precipitates  are 
called  cryoglobulins  (CG),  and  are  classified  under  three  categories  according  to  the  universally 
adopted  classification  of  Brouet [88].  Other  proteins  have  this  particularity  to  precipitate  at  low 
temperature, as cryofibrinogen (CF) (for instance, see the study on clinical cases of patients with either 
CF alone or combined CF plus CG [89]) and cold agglutinins. Proteomic techniques are well adapted 
to determine the protein composition of cryoprecipitates [90]. Cryoproteins are potential biomarkers, 
and pre-analytical precautions have to be taken for their investigation. Indeed, blood must be sampled 
in anticoagulant-free, 37 ° C pre-heated container, handled and centrifuged at 37 ° C, in order to prevent 
cryoprotein elimination by precipitation before analysis. 
Table 1. Main pre-analytical conditions to respect for proteomic analyses of labile blood 
products and blood samples in biomarker discovery field. 
 
Labile blood products  Blood sample for pathological-
case biomarker research 
References 
ECs  PCs  FFP 
Sampling 
sample obtention 
donor position  resting position  [68] 
tourniquet application  less than 30 seconds if possible, no more than 1 minute  [69] 
needle bore size  avoid too thin needle (21–23 gauge needles are preferred)  [70,71] 
container type 
material  approved plastic bags 
vacuette®-like blood collection 
tubes 
[72,73] 
anticoagulant content  Citrate Phosphate Dextrose (CPD)  depends on  analyses  [73] 
processing 
and 
handling 
time between sampling and processing  up to 24 h at +4 ° C or up to 4 h at +24 ° C  [74,75] 
transport time and temperature  controlled transport at +4 ° C, must be as brief as possible  [76] 
centrifugation  prefer centrifugation at +4 ° C, up to 3000 ×  g  [73] 
use of protease inhibitors  required to avoid proteolysis  [78,79] 
use of antioxidant reagents  needed in case of redox proteomic studies  [80,81] 
storage 
temperature 
original sample  +4 ° C  +22 ° C  −25 ° C  −20/−30 ° C or −80 ° C  [73,82,83] 
proteinic extracts  −20/−30 ° C and −80 ° C stored extracts are both suitable  [84] 
freeze/thaw cycles  better only once, but several cycles do not affect proteomic patterns  [73,82,83] 
case of cryoproteins  always work at 37 ° C (pre-heated containers)  [87] Int. J. Mol. Sci. 2010, 11                       
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4. Conclusions 
Pre-analytics is of very high importance for all kind of test, assay and discovery field, and more 
importantly  in  biomarker  discovery  field,  due  to  the  direct  clinical  implications.  Uncontrolled  
pre-analytical parameters may lead to false interpretation of results. 
In  clinical  proteomics,  reproducibility  is  indispensable  and  is  straightly  correlated  with  
pre-analytical considerations. Standardization of sample harvesting, process, and storage has to be set 
up in order to minimize pre-analytical variations. Biomarker discovery is such a complicated field that 
there is no time to waste in wondering if an observed protein variation is due to different physiological 
states or simply to differences in sample handling or storage. Many small-scale standardized protocols 
exist in laboratories and lots of pre-analytical parameters have been investigated so far. Time is now 
about setting up worldwide-scale standardization of sample handling, process and storage.  
The human proteome organization (HUPO) has set up the plasma proteome project (HPPP), in 
order to perform a comprehensive analysis of plasma and serum protein constituents in people. A 
specimen collection and handling committee (SCHC) was created to evaluate pre-analytical variables 
that can potentially impact experiment results. In this purpose, Rai et al. have conducted in 2005 a 
proteomic study, comparing serum and plasma analyses, evaluating storage and handling conditions as 
well as the use of protease inhibitors [91]. They were thus able to present general recommendations 
helping researchers to set up more robust plasma proteome studies. This is an important step towards 
the establishment of standardized protocols for proteome studies, which is primordial in the biomarker 
discovery field.  
This  kind  of initiative is  important  for the transfusion  medicine  community and for the whole 
clinical medicine community as well. Reviews about importance of the pre-analytics in many fields are 
regularly  published  nowadays,  which  means  that  procedures  standardization  is  a  real  
contemporary thought. 
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